MedPath

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer

Phase 3
Completed
Conditions
Metastatic Colorectal Cancer
Interventions
Registration Number
NCT00252564
Lead Sponsor
US Oncology Research
Brief Summary

The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.

Detailed Description

This is a Phase III, open label, nonblinded study. A total of 240 eligible patients will be randomized on a 1:1 basis to either treatment Arm.

In this trial, we will compare the efficacy, safety, and tolerability of this novel combination of biweekly infusional 5-FU/leucovorin plus cetuximab and bevacizumab (FOLF-CB) to the current standard of care, biweekly infusional 5-FU/leucovorin plus oxaliplatin and bevacizumab (Bev-FOLFOX). For practical purposes, this study will be a head to head comparison of oxaliplatin versus cetuximab, since the other components of both regimens will be the same.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
247
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Bev-FOLFOXBevacizumab(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via "T" connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU. Bevacizumab --\> oxaliplatin and LV --\> bolus 5-FU --\> infusional 5-FU Dosing on Days 1 and 15 of each 28-day cycle
Bev-FOLFOXLeucovorin(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via "T" connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU. Bevacizumab --\> oxaliplatin and LV --\> bolus 5-FU --\> infusional 5-FU Dosing on Days 1 and 15 of each 28-day cycle
Bev-FOLFOXOxaliplatin(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via "T" connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU. Bevacizumab --\> oxaliplatin and LV --\> bolus 5-FU --\> infusional 5-FU Dosing on Days 1 and 15 of each 28-day cycle
Bev-FOLFOXFluorouracil(Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via "T" connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU. Bevacizumab --\> oxaliplatin and LV --\> bolus 5-FU --\> infusional 5-FU Dosing on Days 1 and 15 of each 28-day cycle
FOLF-CBFluorouracil(FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU. Cetuximab --\> bevacizumab --\> LV --\> bolus 5-FU --\> infusional 5-FU
FOLF-CBBevacizumab(FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU. Cetuximab --\> bevacizumab --\> LV --\> bolus 5-FU --\> infusional 5-FU
FOLF-CBLeucovorin(FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU. Cetuximab --\> bevacizumab --\> LV --\> bolus 5-FU --\> infusional 5-FU
FOLF-CBCetuximab(FOLF-CB): Cetuximab administered over 2 hours (first dose only; administer all other doses over 1 hour) followed by bevacizumab over 30 minutes, followed by LV over 30 minutes, followed by bolus 5-FU followed by infusional 5-FU. Cetuximab --\> bevacizumab --\> LV --\> bolus 5-FU --\> infusional 5-FU
Primary Outcome Measures
NameTimeMethod
Progression-Free Survival (PFS)12 months

From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).

Kaplan-Meier median PFS time and PFS rate (at 12 months)

Progression-free Survival (PFS) Rate at 1 Year.12 months

From randomization to first progression or death, whichever comes first (event); or first new anti-cancer treatment if before or without progression / death (censoring); or last follow-up date otherwise (censoring).

Secondary Outcome Measures
NameTimeMethod
Overall Survival (OS)up to 4 years

From randomization to death (event); or last follow-up date if alive (censoring).

Kaplan-Meier OS median time.

Objective Response Rate12 months

Percentage of patients with tumor response (by RECIST criteria, including complete response, or CR, i.e. disappearance of all target lesions; and partial response, or PR, i.e. at least a 30% decrease in the sum of the longest diameters of target lesions taking as reference the baseline sum of the longest diameters) among all "per-protocol population" patients.

Trial Locations

Locations (78)

Melbourne Internal Medicine Associates

🇺🇸

Melbourne, Florida, United States

Maryland Oncology Hematology, P.A.

🇺🇸

Columbia, Maryland, United States

Hematology Oncology Associates of Ohio & Michigan

🇺🇸

Lambertville, Michigan, United States

New York Oncology Hematology, PC

🇺🇸

Albany, New York, United States

Raleigh Hematology Oncology Associates

🇺🇸

Cary, North Carolina, United States

Puget Sound Cancer Center-Edmonds

🇺🇸

Edmonds, Washington, United States

Greater Dayton Cancer Center

🇺🇸

Kettering, Ohio, United States

The Texas Cancer Center

🇺🇸

Dallas, Texas, United States

Texas Cancer Center-Sherman

🇺🇸

Sherman, Texas, United States

Hematology Oncology Associates of IL

🇺🇸

Chicago, Illinois, United States

Spalding Oncology Services

🇺🇸

Griffin, Georgia, United States

Cancer Care Associates of Fresno Medical Group, Inc (aka California Cancer Care)

🇺🇸

Fresno, California, United States

Texas Cancer Center

🇺🇸

Arlington, Texas, United States

Integrated Community Oncology Network (ICON) / fka:Florida Oncology Associates

🇺🇸

Jacksonville, Florida, United States

Kansas City Cancer Centers-Southwest

🇺🇸

Overland Park, Kansas, United States

Ocala Oncology Center

🇺🇸

Ocala, Florida, United States

Hope Center

🇺🇸

Terre Haute, Indiana, United States

Auerbach Hematology Oncology Associated

🇺🇸

Baltimore, Maryland, United States

Memorial Sloan-Kettering Cancer Center

🇺🇸

New York, New York, United States

Connecticut Oncology & Hematology, LLP

🇺🇸

Torrington, Connecticut, United States

Cancer Care & Hematology Specialists of Chicagoland

🇺🇸

Niles, Illinois, United States

Kalamazoo Hematology & Oncology

🇺🇸

Kalamazoo, Michigan, United States

Cancer Center of Kansas

🇺🇸

Wichita, Kansas, United States

North Shore Hematology

🇺🇸

East Setauket, New York, United States

Virginia Oncology Associates

🇺🇸

Norfolk, Virginia, United States

Puget Sound Cancer Center Seattle

🇺🇸

Seattle, Washington, United States

Central Indiana Cancer Centers

🇺🇸

Indianapolis, Indiana, United States

Minnesota Oncology Hematology, PA

🇺🇸

Minneapolis, Minnesota, United States

Comprehensive Cancer Centers of Nevada

🇺🇸

Las Vegas, Nevada, United States

Nevada Cancer Centers

🇺🇸

Las Vegas, Nevada, United States

HOAST - Medical Dr.

🇺🇸

San Antonio, Texas, United States

Hematology Oncology Associates

🇺🇸

Phoenix, Arizona, United States

Utah Cancer Specialists

🇺🇸

Salt Lake City, Utah, United States

Brimingham Hematology and Oncology

🇺🇸

Birmingham, Alabama, United States

Rocky Mountain Cancer Center-Midtown

🇺🇸

Denver, Colorado, United States

Willamette Valley Cancer Center

🇺🇸

Eugene, Oregon, United States

Texas Cancer Center-Denton

🇺🇸

Denton, Texas, United States

Tyler Cancer Center

🇺🇸

Tyler, Texas, United States

Texas Cancer Center-Abilene (Shouth)

🇺🇸

Abilene, Texas, United States

Longview Cancer Center

🇺🇸

Longview, Texas, United States

Hematology-Oncology Associates of NNJ, PA

🇺🇸

Morristown, New Jersey, United States

Northwestern Carolina Ocology Hemato

🇺🇸

Hickory, North Carolina, United States

Cancer Centers of the Carolinas

🇺🇸

Greenville, South Carolina, United States

Cancer Center Associates of Carolina, PA / fka Carolina Cancer Center

🇺🇸

Aiken, South Carolina, United States

Texas Oncology Cancer Center

🇺🇸

Austin, Texas, United States

Texas Oncology, P.A.

🇺🇸

Webster, Texas, United States

West Texas Cancer Center

🇺🇸

Odessa, Texas, United States

Mamie McFaddin Ward Cancer Center

🇺🇸

Beaumont, Texas, United States

Texas Oncology, PA - Bedford

🇺🇸

Bedford, Texas, United States

Texas Oncology, PA

🇺🇸

Webster, Texas, United States

El Paso Cancer Treatment Ctr

🇺🇸

El Paso, Texas, United States

Lake Vista Cancer Center

🇺🇸

Lewisville, Texas, United States

San Antonio Tumor & Blood Clinic

🇺🇸

Fredericksburg, Texas, United States

Allison Cancer Center

🇺🇸

Midland, Texas, United States

South Texas Cancer Center-McAllen

🇺🇸

McAllen, Texas, United States

Northern AZ Hematology & Oncology Assoc

🇺🇸

Sedona, Arizona, United States

Florida Cancer Institute

🇺🇸

New Port Richey, Florida, United States

Business Office - ACRC

🇺🇸

Tucson, Arizona, United States

Monterey Bay Oncology

🇺🇸

Monterey, California, United States

Medical Oncology Associates of Augusta PC

🇺🇸

Augusta, Georgia, United States

Cancer Centers of Florida, P.A.

🇺🇸

Ocoee, Florida, United States

Fort Wayne Medical Oncology Hematology, Inc

🇺🇸

Fort Wayne, Indiana, United States

Greeley Medical Clinic Oncology Hematology, PC

🇺🇸

Greeley, Colorado, United States

Iowa Blood and Cancer Care

🇺🇸

Cedar Rapids, Iowa, United States

Center for Cancer & Blood Disorders

🇺🇸

Bethesda, Maryland, United States

Louisiana Hematology Oncology Associates

🇺🇸

Baton Rouge, Louisiana, United States

Missouri Cancer Associates

🇺🇸

Columbia, Missouri, United States

Osteopathic Medical Oncology and Hematology

🇺🇸

Clinton Township, Michigan, United States

Medical Oncology Associates

🇺🇸

Kingston, Pennsylvania, United States

Texas Cancer Center at Medical City

🇺🇸

Dallas, Texas, United States

C. Michael Jones, MD

🇺🇸

Germantown, Tennessee, United States

Paris Regional Cancer Center

🇺🇸

Paris, Texas, United States

Texas Cancer Center of Mesquite

🇺🇸

Mesquite, Texas, United States

Texas Oncology Cancer Center-Sugar Land

🇺🇸

Sugar Land, Texas, United States

Waco Cancer Care and Research Center

🇺🇸

Waco, Texas, United States

Northwest Cancer Specialists-Vancouver

🇺🇸

Vancouver, Washington, United States

Yakima Valley mem Hosp/North Star Lodge

🇺🇸

Yakima, Washington, United States

Cancer Care Northwest-South

🇺🇸

Spokane, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath